Showing results (61-70 of 237) with videos related to

Sort By:
Pageof 24
Annals of Hematology|May 24, 2020
Long-term survival and polyclonal immunoglobulin reconstitution after allogeneic stem cell transplantation in multiple myelomaChristine Eisfeld, Eva Eßeling, Ramona Wullenkord, et al.
Cancer|January 31, 2018
Efficacy and safety analysis by age cohort of inotuzumab ozogamicin in patients with relapsed or refractory acute lymphoblastic leukemia enrolled in INO-VATEElias J Jabbour, Daniel J DeAngelo, Matthias Stelljes, et al.
Cancer|May 5, 2016
Blinatumomab treatment of older adults with relapsed/refractory B-precursor acute lymphoblastic leukemia: Results from 2 phase 2 studiesHagop M Kantarjian, Anthony S Stein, Ralf C Bargou, et al.
Bone Marrow Transplantation|September 2, 2023
The role of anti-thymocyte globulin in allogeneic stem cell transplantation (HSCT) from HLA-matched unrelated donors (MUD) for secondary AML in remission: a study from the ALWP /EBMTArnon Nagler, Myriam Labopin, Nicolaus Kröger, et al.
British Journal of Haematology|June 4, 2024
Early blast clearance during sequential conditioning prior to allogeneic stem cell transplantation in patients with acute myeloid leukaemiaJulian Ronnacker, Marc-Andre Urbahn, Christian Reicherts, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 1, 2019
Outcomes of Allogeneic Stem Cell Transplantation after Inotuzumab Ozogamicin Treatment for Relapsed or Refractory Acute Lymphoblastic LeukemiaDavid I Marks, Partow Kebriaei, Matthias Stelljes, et al.
The Journal of Experimental Medicine|November 17, 2010
Targeting of B and T lymphocyte associated (BTLA) prevents graft-versus-host disease without global immunosuppressionJörn C Albring, Michelle M Sandau, Aaron S Rapaport, et al.
The Lancet. Haematology|March 31, 2023
Defibrotide plus best standard of care compared with best standard of care alone for the prevention of sinusoidal obstruction syndrome (HARMONY): a randomised, multicentre, phase 3 trialStephan A Grupp, Selim Corbacioglu, Hyoung Jin Kang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 17, 2009
Bortezomib, dexamethasone, and fibroblast growth factor receptor 3-specific tyrosine kinase inhibitor in t(4;14) myelomaGuido Bisping, Doris Wenning, Martin Kropff, et al.
Bone Marrow Transplantation|August 18, 2022
Thiotepa-fludarabine-treosulfan conditioning for 2nd allogeneic HCT from an alternative unrelated donor for patients with AML: a prospective multicenter phase II trialJürgen Finke, Claudia Schmoor, Matthias Stelljes, et al.
Pageof 24